Perrigo Company plc vs Travere Therapeutics, Inc.: Strategic Focus on R&D Spending

Divergent R&D Strategies: Perrigo vs. Travere

__timestampPerrigo Company plcTravere Therapeutics, Inc.
Wednesday, January 1, 201415250000047795223
Thursday, January 1, 201518780000050426000
Friday, January 1, 201618400000070853000
Sunday, January 1, 201716770000078168000
Monday, January 1, 2018218600000123757000
Tuesday, January 1, 2019187400000140963000
Wednesday, January 1, 2020177700000131773000
Friday, January 1, 2021122000000210328000
Saturday, January 1, 2022123100000235780000
Sunday, January 1, 2023122500000244990000
Loading chart...

Unveiling the hidden dimensions of data

Strategic R&D Investments: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Perrigo Company plc and Travere Therapeutics, Inc. have demonstrated contrasting strategies in their R&D investments.

From 2014 to 2023, Perrigo's R&D expenses have shown a steady decline, dropping by approximately 20% from their peak in 2018. This trend suggests a strategic shift, possibly towards cost optimization or a focus on other business areas. In contrast, Travere Therapeutics has aggressively increased its R&D spending, with a remarkable 413% surge over the same period. By 2023, Travere's R&D expenses were nearly double those of Perrigo, highlighting its strategic focus on innovation and development.

These divergent paths underscore the varied approaches companies take in navigating the ever-evolving pharmaceutical industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025